(Q35609738)

9 August 2017

1 reference

title

Behavioural effects of the newer antiepileptic drugs: an update (English)

1 reference

9 August 2017

Frank M C Besag

1

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 January 2004

1 reference

Expert Opinion on Drug Safety

9 August 2017

published in

1 reference

9 August 2017

volume

3

1 reference

9 August 2017

issue

1

1 reference

9 August 2017

page(s)

1-8

1 reference

Behavioural effects of the new anticonvulsants

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.1

Childhood epilepsy in relation to mental handicap and behavioural disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.1

Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.1

Vigabatrin and behaviour disturbances.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.1

21 January 2018

Vigabatrin and psychosis

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.1

Psychiatric adverse events during vigabatrin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.1

Vigabatrin and behaviour disorders: a retrospective survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.1

Severe persistent visual field constriction associated with vigabatrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.1

Mental and behavioural outcome of infantile epilepsy treated by vigabatrin in tuberous sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.1

An audit of topiramate use in a general neurology clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.1

Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.1

Hypomania induced by gabapentin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.1

Gabapentin toxicity in children manifesting as behavioral changes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.1

Psychiatric symptoms after therapy with new antiepileptic drugs: psychopathological and seizure related variables

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.1

Acute psychotic symptoms induced by topiramate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.1

Topiramate and psychiatric adverse events in patients with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.1

Topiramate in clinical practice: first year's postlicensing experience in a specialist epilepsy clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.1

A pilot study of topiramate as monotherapy in the treatment of acute mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.1

Use of topiramate, a new anti-epileptic as a mood stabilizer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.1

Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.1

Review of the use of topiramate for treatment of bipolar disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.1

Treatment of acute mania with topiramate in hospitalized patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.1

The use of topiramate in mood stabilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.1

Topiramate induced manic episode

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.1

Confusion and dysphoria with low-dose topiramate in a patient with bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.1

Occurrence of psychosis in patients with epilepsy randomized to tiagabine or placebo treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.1

Neuropsychological effects of tiagabine, a potential new antiepileptic drug.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.1

Nonconvulsive status epilepticus in two patients receiving tiagabine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.1

Oxcarbazepine in bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.1

Oxcarbazepine in affective and schizoaffective disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.1

A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.1

A systematic review of the safety profile of levetiracetam: a new antiepileptic drug.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.1

Levetiracetam psychosis in children with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.1

Felbamate as add-on therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.1

Felbamate monotherapy has stimulant-like effects in patients with epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.1

Felbamate in epilepsy therapy: evaluating the risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.1

The first open study of zonisamide, a novel anticonvulsant, shows efficacy in mania.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.1

Tiagabine-induced absence status in idiopathic generalized epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.1

Acute psychological disorders in patients with epilepsy: a nation-wide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.1.1

21 January 2018

Identifiers

DOI

10.1517/14740338.3.1.1

1 reference

9 August 2017

1 reference